NEW YORK; Apr. 22, 2015 – Accenture (NYSE: ACN) has expanded the Accenture Life Sciences Cloud for Research and Development (R&D) powered by Oracle with the addition of enhanced clinical data management capabilities. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market.
This latest version of the Accenture Life Sciences Cloud for R&D offers the Oracle Health Sciences Data Management Workbench (DMW), which includes prebuilt integrations to the Oracle Health Sciences InForm, an electronic data capture (EDC) solution to create an end-to-end clinical data collection and management platform.
With the addition of the Oracle Health Sciences DMW, the Accenture Life Sciences Cloud for R&D automates the time-consuming and resource-intensive manual processes required to load, transform and clean trial data. Trial sponsors and contract research organizations will now be able to increase the speed and accuracy of data collection, integration and analysis; achieve greater efficiency of clinical workflow and query management; and accelerate stakeholders’ access to data across the trial lifecycle from source to submission.
The Oracle Health Sciences DMW provides the Accenture Life Sciences Cloud for R&D with several key benefits, including:
Additionally, the Oracle Health Sciences DMW in the Accenture Life Sciences Cloud for R&D is pre-integrated with the Oracle Health Sciences InForm EDC platform. The latest release of InForm, version 6.1, enables fully integrated capabilities including coding and IRT, rapid and reliable trial builds, and one-click, self-service deployment, including mid-study changes. As a result, life sciences organizations gain a seamless flow of data, from electronic data capture to data management to analysis.
“Being able to take advantage of new technologies for clinical data management in combination with Oracle InForm is a key factor to helping our clients bring life-improving medicines to patients faster,” said Kevin Julian, managing director of Accelerated R&D Services, Accenture Life Sciences. “This latest version of Accenture Life Sciences Cloud for R&D harnesses the highly differentiated capabilities of a pre-integrated end-to-end clinical R&D platform based on leading technology from Oracle.”
The combined solution from Accenture – a Diamond-level member of Oracle PartnerNetwork - and Oracle bring together Oracle’s experience in developing and hosting mission-critical clinical data warehousing and analytics applications for life sciences with Accenture’s proven implementation capabilities to deliver service-based solutions.
“As the industry’s only true end-to-end data management solution in a single environment, Oracle Health Sciences Data Management Workbench accelerates the speed and accuracy of clinical data integration, reconciliation, aggregation, and analysis by reducing time -consuming manual processes required to load, transform, and clean trial data. Accenture’s Life Sciences Cloud for R&D with Data Management Workbench is changing the way technology is developed and delivered across the life sciences industry, helping life sciences organizations provide life-improving therapies faster and at a lower cost,” said Steve Rosenberg, general manager of Oracle’s Health Sciences Global Business Unit. “We at Oracle are proud that our industry-leading cloud solutions are at the heart of this leading capability.”
As previously announced in October, the Life Sciences Cloud Coalition is a ground-breaking initiative, in parallel with the Accenture Life Sciences Cloud for R&D platform, to build an assembly of like-minded leaders, collaborating for a healthier industry in non-competitive areas. The focus of the coalition is on driving innovation in the Accenture Life Sciences Cloud to digitally enable the R&D function, speed the drug development process while improving quality and cost for the industry. Members of the Life Sciences Cloud Coalition include Accenture, Oracle, Eisai, Pfizer, Merck, and other leading pharmaceutical companies.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.